Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Equity Average (2016 - 2025)

Historic Equity Average for Perspective Therapeutics (CATX) over the last 14 years, with Q3 2025 value amounting to $254.0 million.

  • Perspective Therapeutics' Equity Average fell 2413.26% to $254.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.0 million, marking a year-over-year decrease of 2413.26%. This contributed to the annual value of $182.9 million for FY2024, which is 18180.88% up from last year.
  • Perspective Therapeutics' Equity Average amounted to $254.0 million in Q3 2025, which was down 2413.26% from $275.2 million recorded in Q2 2025.
  • Over the past 5 years, Perspective Therapeutics' Equity Average peaked at $334.7 million during Q3 2024, and registered a low of $40.4 million during Q1 2021.
  • In the last 5 years, Perspective Therapeutics' Equity Average had a median value of $87.0 million in 2023 and averaged $145.8 million.
  • In the last 5 years, Perspective Therapeutics' Equity Average surged by 113095.77% in 2021 and then crashed by 2413.26% in 2025.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Equity Average stood at $65.1 million in 2021, then fell by 13.68% to $56.2 million in 2022, then skyrocketed by 54.84% to $87.0 million in 2023, then soared by 255.93% to $309.6 million in 2024, then dropped by 17.97% to $254.0 million in 2025.
  • Its Equity Average stands at $254.0 million for Q3 2025, versus $275.2 million for Q2 2025 and $287.7 million for Q1 2025.